Catch up on key late-breaking research from Abbott, Edwards Lifesciences and Philips presented at the four-day meeting in Paris. 

Interventional cardiologists in Detroit developed the new technique with a specific patient in mind. One specialist described it as an "exciting breakthrough."

The World Health Organization has published a new guideline recommending against the use of artificial sweeteners such as aspartame and sucralose to lose weight or reduce the risk of noncommunicable diseases.

The new drug, asundexian, is currently the subject of two multicenter Phase III studies—the OCEANIC-AF trial and OCEANIC-STROKE trial—focused on its safety and efficacy.

“These and other data support that young adults do as well as a more traditional patient population when looking at arrhythmia-free survival,” researchers wrote.

“I was ready to make out my will, so this came along just at the right time,” the 76-year-old patient said. 

In addition to these 15 late-breaking clinical studies, TVT 2023 will feature live cases, hands-on training, poster presentations and much more.

A new-look TAVR valve was tested on patients for the first time, leading researchers to say its use appears to be "feasible and safe." More research, of course, is still required.